Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities — Hope S Rugo, MD

CME information and select publications

Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo, including the following topics:

• Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00)
• First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04)
• Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (24:11)
• Beyond the Guidelines Survey (35:36)
• Faculty Case Presentations (51:27)

CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Nontargeted Therapy for Lung Cancer — Dr Goldberg (9:07)
• Targeted Therapy for Non-Small Cell Lung Cancer — Dr Sabari (51:19)

CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Hormone Receptor-Positive Breast Cancer — Dr O’Shaughnessy (10:45)
• Management of Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Wander (40:47)

CME information and select publications

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma — Gilles Salles, MD, PhD

CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics:

• Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
• Natural history of FL and current treatment landscape in the first-line setting (5:20)
• Testing approaches for the detection of EZH2 mutations (14:37)
• Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
• Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
• Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
• Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
• Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
• Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
• Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
• Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
• Perspectives on the future treatment landscape of FL (54:29)

CME information and select publications

Featuring an interview with Dr Stephen V Liu, including the following topics:

• Management of localized non-small cell lung cancer (NSCLC) (0:00)
• First-line treatment of advanced NSCLC (10:53)
• Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24)
• Recent FDA approvals for NSCLC (37:49)
• Recent advances in small cell lung cancer (47:14)
• Lurbinectidin in combination with atezolizumab as front-line maintenance therapy for patients with early-stage SCLC (52:33)

CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics:

• Introduction (0:00)
• Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56)
• Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48)

CME information and select publications